OKYO Pharma (OKYO) Receivables - Net (2021 - 2026)

OKYO Pharma (OKYO) has reported Receivables - Net for 6 consecutive years, with $375749.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Net rose 55.05% year-over-year to $375749.0 in Q1 2026; TTM through Mar 2026 was $375749.0, a 55.05% increase from a year earlier, with the FY2026 full-year figure at $375749.0, up 55.05% from the prior year.
• Receivables - Net was $375749.0 for Q1 2026 at OKYO Pharma, up from $242342.0 in the prior quarter.
• Over five years, Receivables - Net peaked at $812956.0 in Q1 2022 and troughed at $151938.0 in Q1 2024.
• A 5-year average of $435036.0 and a median of $375749.0 in 2026 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net soared 1774.47% in 2022 and slumped 74.34% in 2024, its largest moves.
• Over 5 years, Receivables - Net stood at $812956.0 in 2022, then decreased by 27.16% to $592195.0 in 2023, then slumped by 74.34% to $151938.0 in 2024, then surged by 59.5% to $242342.0 in 2025, then soared by 55.05% to $375749.0 in 2026.
• The last three Receivables - Net figures came in at $375749.0 (Q1 2026), $242342.0 (Q1 2025), and $151938.0 (Q1 2024), per Business Quant data.